<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344238</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00030913</org_study_id>
    <nct_id>NCT02344238</nct_id>
  </id_info>
  <brief_title>Smart Capsule for Automatic Adherence Monitoring</brief_title>
  <official_title>Smart Capsule for Automatic Adherence Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In pharmacotherapy trials in drug-dependent populations, medication compliance is a
      significant issue, as rates tend to be low and adherence to medication may predict improved
      outcomes (Baros et al, 2007; McRae et al, 2004; O'Brien et al, 1996; Somoza et al., 2010).
      However, methods commonly used to determine compliance may result in inaccurate measurement
      of adherence. It is therefore essential to develop measurement systems that not only
      accurately and objectively measure compliance, but can also have the potential to increase
      compliance in difficult to treat disorders such as addiction. In this study, we propose to
      assess the acceptability, tolerability, and efficacy of the ID-Cap System, a novel compliance
      measurement device, in a healthy population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the clinical trial is to evaluate the acceptability, tolerability,
      and efficacy of the ID-Cap System in a healthy population.

      Participation in the study takes 10 visits over a period of approximately five weeks. The
      first visit is a screening visit to determine if participants are eligible to participate.
      After inclusion into the study, participants will be randomized into one of three groups.
      Participants randomized to Group 1 will have compliance measured by patient reports, pill
      count, and riboflavin measurement. Participants randomized to Group 2 will have compliance
      measured by patient reports, pill count, riboflavin measurement, and data collected by the
      e-Tect reader. Participants randomized to Group 3 will also have compliance measured by
      patient reports, pill count, riboflavin measurement, and data collected by the ID-Cap reader.
      However, participants randomized to this group will also receive reminder calls and/or text
      messages to ingest the study medication if a signal is not sent from the ID-Cap reader to the
      study team within one hour of the scheduled medication administration time.

      After the initial screening visit, participants will present to the clinic twice weekly to
      complete self-reports of compliance, provide urine samples for riboflavin assessment, and be
      assessed for adverse effects.

      They will also be asked to attend one follow-up visit to include abdominal x-ray in order to
      confirm passage of the capsules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>30 days</time_frame>
    <description>The primary outcome will be medication adherence as measured by percentage of doses taken among groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>A secondary outcome will be safety and tolerability of ingestion of the ID Cap as measured by number of participants reporting adverse events in Group 1 who received standard capsules (no ID technology, study Arm 1) and Group 2 who received ID-Capsules (study Arms 2 and 3).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Standard Capsules</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID Capsules without Prompts</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID Capsules with Prompts</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ID Capsule</intervention_name>
    <description>Capsule containing ingestible sensor</description>
    <arm_group_label>ID Capsules with Prompts</arm_group_label>
    <arm_group_label>ID Capsules without Prompts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>50mg</description>
    <arm_group_label>ID Capsules with Prompts</arm_group_label>
    <arm_group_label>ID Capsules without Prompts</arm_group_label>
    <arm_group_label>Standard Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prompts</intervention_name>
    <description>Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.</description>
    <arm_group_label>ID Capsules with Prompts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be between the ages of 18 and 65 years

          -  Must have BMI within range of 18-30

          -  If female and of childbearing potential, must agree to use acceptable methods of birth
             control for the duration of the trial

          -  Must consent to random assignment, and be willing to commit to medication ingestion

          -  Must be able to read and provide informed consent

          -  Must function at an intellectual level sufficient to allow accurate completion of
             assessments

        Exclusion Criteria:

          -  Women who are pregnant, nursing, or plan to become pregnant during the course of the
             study, as abdominal X-rays will be completed on all participants

          -  Must not have evidence of a significant medical condition which may affect capsule
             passage through the gastrointestinal tract (including, but not limited to, Crohn's
             disease, small bowel tumors, intestinal adhesions, ulcerations, and radiation
             enteritis)

          -  Must not have past or current psychotic or bipolar disorder

          -  Must not be currently dependent on substances, with the exception of nicotine or
             caffeine, within the past 60 days

          -  Hypersensitivity to adhesive, riboflavin, or any capsule component

          -  Patients who, in the investigator's opinion, would be unable to comply with study
             procedures or assessments, or would be unacceptable study candidates (e.g., poses
             threat to staff)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee McRae-Clark, PharmD, BCPP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <results_first_submitted>February 22, 2018</results_first_submitted>
  <results_first_submitted_qc>February 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Aimee McRae-Clark</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Medication compliance</keyword>
  <keyword>Technology</keyword>
  <keyword>Drug study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Capsules</title>
          <description>Compliance measured by self-report and riboflavin measurement.
Riboflavin: 50mg</description>
        </group>
        <group group_id="P2">
          <title>ID Capsules Without Prompts</title>
          <description>Compliance measured by self-report, riboflavin measurement, and data collected by the ID Cap.
ID Cap: Capsule-encased computer chip
Riboflavin: 50mg</description>
        </group>
        <group group_id="P3">
          <title>ID Capsules With Prompts</title>
          <description>Compliance measured by self-report, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
ID Cap: Capsule-encased computer chip
Riboflavin: 50mg
Prompts: Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Capsules</title>
          <description>Compliance measured by self-report and riboflavin measurement.
Riboflavin: 50mg</description>
        </group>
        <group group_id="B2">
          <title>ID Capsules Without Prompts</title>
          <description>Compliance measured by self-report, riboflavin measurement, and data collected by the ID Cap.
ID Cap: Capsule-encased computer chip
Riboflavin: 50mg</description>
        </group>
        <group group_id="B3">
          <title>ID Capsules With Prompts</title>
          <description>Compliance measured by self-report, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
ID Cap: Capsule-encased computer chip
Riboflavin: 50mg
Prompts: Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Medication Adherence</title>
        <description>The primary outcome will be medication adherence as measured by percentage of doses taken among groups.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Capsules</title>
            <description>Received standard capsules, with adherence measured by self-report, pill count and riboflavin measurement.
Riboflavin: 50mg</description>
          </group>
          <group group_id="O2">
            <title>ID Capsules Without Prompts</title>
            <description>Received ID capsules, with adherence measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
ID Cap: Capsule containing ingestible sensor
Riboflavin: 50mg</description>
          </group>
          <group group_id="O3">
            <title>ID Capsules With Prompts</title>
            <description>Received ID capsules, with adherence measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
ID Cap: Capsule containing ingestible sensor
Riboflavin: 50mg
Prompts: Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>The primary outcome will be medication adherence as measured by percentage of doses taken among groups.</description>
          <units>percentage of doses taken (pill count)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" lower_limit="82.4" upper_limit="93.7"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O3" value="94.4" lower_limit="89.5" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Adverse Events</title>
        <description>A secondary outcome will be safety and tolerability of ingestion of the ID Cap as measured by number of participants reporting adverse events in Group 1 who received standard capsules (no ID technology, study Arm 1) and Group 2 who received ID-Capsules (study Arms 2 and 3).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Capsules</title>
            <description>Received standard capsules (no ID cap technology).</description>
          </group>
          <group group_id="O2">
            <title>ID Capsules</title>
            <description>Received ID capsules: capsules containing ingestible sensor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events</title>
          <description>A secondary outcome will be safety and tolerability of ingestion of the ID Cap as measured by number of participants reporting adverse events in Group 1 who received standard capsules (no ID technology, study Arm 1) and Group 2 who received ID-Capsules (study Arms 2 and 3).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Capsules</title>
          <description>Compliance measured by self-report, pill count and riboflavin measurement (study Arm 1)
Riboflavin: 50mg</description>
        </group>
        <group group_id="E2">
          <title>ID Capsules</title>
          <description>Compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap (study Arms 2 and 3).
ID Cap: Capsule-encased computer chip
Riboflavin: 50mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Other GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited generalizability- participants were primarily MUSC students &amp; staff. The ID Cap system is only available for adherence measurement for solid oral dosage medications. Potential for user error due to the electronic nature of the ID Cap system.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Aimee McRae-Clark</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <email>mcraeal@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

